$14.80 Million in Sales Expected for Antares Pharma, Inc. (ATRS) This Quarter

Equities analysts forecast that Antares Pharma, Inc. (NASDAQ:ATRS) will post $14.80 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Antares Pharma’s earnings, with the highest sales estimate coming in at $17.30 million and the lowest estimate coming in at $12.11 million. Antares Pharma posted sales of $14.20 million in the same quarter last year, which suggests a positive year-over-year growth rate of 4.2%. The business is expected to announce its next quarterly earnings results on Tuesday, March 13th.

According to Zacks, analysts expect that Antares Pharma will report full year sales of $14.80 million for the current fiscal year, with estimates ranging from $52.58 million to $58.20 million. For the next year, analysts expect that the company will report sales of $77.33 million per share, with estimates ranging from $64.00 million to $101.30 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow Antares Pharma.

Antares Pharma (NASDAQ:ATRS) last issued its earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.03). The firm had revenue of $15.10 million for the quarter, compared to the consensus estimate of $14.01 million. Antares Pharma had a negative net margin of 32.06% and a negative return on equity of 43.05%. The business’s quarterly revenue was up 11.9% on a year-over-year basis.

Several brokerages have recently issued reports on ATRS. HC Wainwright set a $5.00 target price on shares of Antares Pharma and gave the stock a “buy” rating in a research note on Friday, October 13th. Piper Jaffray Companies reissued a “buy” rating on shares of Antares Pharma in a report on Friday, September 8th. Finally, ValuEngine cut shares of Antares Pharma from a “hold” rating to a “sell” rating in a report on Monday, October 16th. One analyst has rated the stock with a sell rating, three have assigned a buy rating and two have assigned a strong buy rating to the company. Antares Pharma currently has a consensus rating of “Buy” and a consensus price target of $3.84.

In other news, Director Thomas J. Garrity sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 3rd. The shares were sold at an average price of $3.50, for a total transaction of $105,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Leonard S. Jacob sold 230,000 shares of the business’s stock in a transaction that occurred on Monday, October 9th. The shares were sold at an average price of $4.05, for a total transaction of $931,500.00. The disclosure for this sale can be found here. 11.60% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. raised its holdings in shares of Antares Pharma by 10.2% during the first quarter. Schwab Charles Investment Management Inc. now owns 289,093 shares of the specialty pharmaceutical company’s stock valued at $822,000 after purchasing an additional 26,847 shares during the last quarter. State Board of Administration of Florida Retirement System increased its holdings in Antares Pharma by 95.0% during the third quarter. State Board of Administration of Florida Retirement System now owns 59,413 shares of the specialty pharmaceutical company’s stock valued at $192,000 after buying an additional 28,940 shares during the last quarter. MML Investors Services LLC increased its holdings in Antares Pharma by 228.2% during the second quarter. MML Investors Services LLC now owns 43,147 shares of the specialty pharmaceutical company’s stock valued at $139,000 after buying an additional 30,000 shares during the last quarter. First Eagle Investment Management LLC increased its holdings in Antares Pharma by 150.0% during the third quarter. First Eagle Investment Management LLC now owns 50,000 shares of the specialty pharmaceutical company’s stock valued at $162,000 after buying an additional 30,000 shares during the last quarter. Finally, Capital Advantage Inc. purchased a new stake in Antares Pharma during the third quarter valued at approximately $110,000. 34.65% of the stock is owned by hedge funds and other institutional investors.

Shares of Antares Pharma (NASDAQ ATRS) traded up $0.01 during midday trading on Monday, hitting $2.02. 1,062,206 shares of the stock traded hands, compared to its average volume of 1,523,031. Antares Pharma has a 52-week low of $1.58 and a 52-week high of $4.09. The company has a debt-to-equity ratio of 0.69, a quick ratio of 2.89 and a current ratio of 3.34.

WARNING: This piece of content was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://sportsperspectives.com/2017/12/18/14-80-million-in-sales-expected-for-antares-pharma-inc-atrs-this-quarter.html.

Antares Pharma Company Profile

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.

Get a free copy of the Zacks research report on Antares Pharma (ATRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply